Health Care · Surgical & Medical Instruments & Apparatus

TNDM TANDEM DIABETES CARE INC SEC Filings & Insider Trading Activity 2026

company
CIK 1438133133 filings
Russell 2000

TNDM at a glance

TANDEM DIABETES CARE INC (TNDM, SEC CIK 1438133) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), TANDEM DIABETES CARE INC (TNDM) reported revenue of $1.0 billion (up 7.9% from FY2024) and a net loss of $204.7 million. Diluted EPS was -$3.04.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding TANDEM DIABETES CARE INC (TNDM) shares worth $551.6 million in 13F-HR filings.
  • In the last 90 days, TNDM insiders reported 0 open-market purchases ($0) and 1 open-market sale ($33K) on Form 4, a net sale of $33K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.0B
+7.9% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$33K
13F holders
28 funds
$551.6M · −2 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Design, development, and commercialization of advanced insulin delivery and diabetes technology with AID systems featuring Control-IQ+ hybrid closed-loop technology
  • New product emphasis: Expanded commercial availability of Tandem Mobi with Android control (2025) and Control-IQ+ algorithm cleared for type 2 diabetes (18+ years) in 2025
  • Strategic shift: Beginning direct sales, training, and support in UK, Austria, Switzerland (2026), transitioning from distributor model internationally
  • Quantitative highlight: Serving nearly 500,000 people in 25+ countries with estimated addressable market expansion to type 2 insulin-dependent diabetes patients beginning 2025
  • Noteworthy fact: Launch of next-generation Mobi patch pump and extended-wear infusion set pipeline targeting fully closed-loop technology and device miniaturization

Risk Factors

  • Cybersecurity risk managed by dedicated Incident Management Team led by VP, Cybersecurity with 20+ years industry experience
  • Escalation protocols include disclosure committee and Cybersecurity and Data Privacy Oversight Committee to address significant incidents
  • Regular detailed cybersecurity threat and mitigation reports reviewed by Cybersecurity and Data Privacy Oversight Committee and full Board
  • Integration of cybersecurity risk considerations into overall risk management and budgeting controlled by VP, Cybersecurity
  • Cross-departmental leadership on cybersecurity includes Chief HR Officer, VP Privacy, legal, finance, and business unit personnel

Management Discussion & Analysis

  • Revenue $1.015B in 2025, up 8% YoY from $940.2M in 2024; U.S. sales $706.9M (+5%), international $307.8M (+15%)
  • Gross margin 54% in 2025 vs 52% in 2024; operating loss $(187.3M) vs $(99.1M) reflecting higher operating expenses ($733.3M vs $588.7M)
  • Best segment: International sales growth +$40.3M to $307.8M driven by volumes, price, and FX; worst: U.S. pumps with slower shipment growth (~81K to 86K units)
  • Cash flow: Operating cash used $(9.7M) vs provided $24.2M; investing cash provided $72.9M due to short-term investment maturities; financing used $43.4M mainly for debt repayment
  • Outlook: Transition to pharmacy benefit "pay as you go" reimbursement in 2026 may reduce upfront pump sales, increase supply sales; regulatory, reimbursement, and macroeconomic risks noted

AI summary of the TNDM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $283.7M, up $34.4M YoY from $249.3M, driven by volumes, pricing and channel mix
  • Gross margin 57% vs 54% YoY; operating loss $2.4M vs $22.9M
  • Best performer: international supplies and other sales $61.1M vs $48.3M; U.S. pump sales $83.4M vs $84.8M
  • Cash and investments $443.1M; operating cash use $24.4M through nine months, financing provided $269.3M
  • Headwinds: infusion-set inventory constraints expected through early 2027; pharmacy pay-as-you-go model initially reduces pump sales and gross profit

Risk Factors

  • Newly added trade-policy risk: tariff uncertainty affecting Mexico and China imports, with supplier changes potentially requiring costly regulatory resubmissions
  • Most material operational update: infusion-set supplier constraints impacting inventory and supply sales, expected to persist through early 2027
  • Regulatory and reimbursement risk: CMS finalized competitive bidding and monthly rental payment changes for insulin pumps on December 2, 2025
  • Competitive market risk: GLP-1 adoption since 2023 likely reduced demand across the insulin therapy market
  • Financial risk: $443.1 million in cash, cash equivalents and short-term investments against $316.3 million 2029 Notes and $300.0 million 2032 Notes

AI summary of the TNDM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 8.01: Other Events

  • FDA 510(k) clearance received November 12, 2026 for Tandem Mobi tubeless automated insulin delivery system
  • Tubeless infusion set cleared for up to 7 days, while cartridge remains cleared for 3 days
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 sales $283.7M, up 14%, with international growth 26% versus U.S. growth 9%
  • Gross margin 57%, up 270 basis points, while operating loss narrowed to $2.4M from $22.9M
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 sales rose 6% to $254.6M, with U.S. growth 5% and international growth 7%
  • Gross margin reached 57%, up from 52%, while adjusted EBITDA improved to $6.4M from negative $1.8M

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Tandem Diabetes Care’s financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed quarterly financial results and management commentary

AI summaries of TNDM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TNDM

Don't miss the next TNDM filing

  • Alerts as it files. A push when TNDM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TNDM, by share count.
  • Ask anything. An AI agent that reads every TNDM filing and answers with sources.

TNDM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Kyrillos Jean-ClaudeANov 16, 2026$11.51
Morrison SusanMNov 15, 2026-
Morrison SusanMNov 15, 2026-
Morrison SusanMNov 15, 2026-
Beaver SandraMNov 15, 2026-
Beaver SandraMNov 15, 2026-
Morrison SusanFNov 15, 2026$20.07
Morrison SusanFNov 15, 2026$20.07

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$747.7M$940.2M$1.0B
Gross Profit-$489.6M$546.0M
Operating Income--$99.1M-$187.3M
Net Income--$96.0M-$204.7M
Gross Margin-52.1%53.8%
Op. Margin--10.5%-18.5%
Net Margin--10.2%-20.2%
Balance Sheet
Total Assets-$967.7M$881.1M
Equity$313.6M$263.1M$155.2M
ROE--36.5%-131.9%
Per Share
EPS-$-1.47$-3.04
Cash Flow
Operating CF-$24.2M-$9.7M
CapEx-$19.2M$19.9M

Source: XBRL data in TANDEM DIABETES CARE INC (TNDM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TNDM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TNDM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$551.6M
Q2 202630$487.7M
Q1 202630$645.0M
Q4 202527$747.0M
Q3 202529$390.0M
Q2 202529$598.6M
Q1 202527$347.3M
Q4 202428$566.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 228 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TNDM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
8-KNov 13, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 29, 2026--
4Oct 19, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 17, 2026--
4Jun 4, 2026-
4Jun 2, 2026-

Related Health Care companies

All Health Care →

TNDM SEC filings: frequently asked questions

Are TNDM insiders buying or selling?

In the last 90 days, TANDEM DIABETES CARE INC (TNDM) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $32,555 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TNDM stock?

As of September 30, 2026, the largest TANDEM DIABETES CARE INC (TNDM) holders among the 13F filers tracked by SignalX were BlackRock ($192.0 million), Vanguard Portfolio Management LLC ($63.0 million), Vanguard Capital Management LLC ($49.6 million), State Street Corp ($47.1 million), Goldman Sachs Group ($41.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TNDM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), TANDEM DIABETES CARE INC (TNDM) reported revenue of $1.0 billion (up 7.9% from FY2024) and a net loss of $204.7 million. Diluted EPS was -$3.04. The figures come from the XBRL data in the 10-K.

What are the main risks in TNDM's latest 10-K?

In the 10-K filed February 19, 2026, TANDEM DIABETES CARE INC (TNDM) flagged: Cybersecurity risk managed by dedicated Incident Management Team led by VP, Cybersecurity with 20+ years industry experience. Escalation protocols include disclosure committee and Cybersecurity and Data Privacy Oversight Committee to address significant incidents. (AI summary of the Risk Factors section.)

What did TNDM report in its latest 8-K?

TANDEM DIABETES CARE INC (TNDM) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). FDA 510(k) clearance received November 12, 2026 for Tandem Mobi tubeless automated insulin delivery system.

What are the latest TNDM SEC filings?

TANDEM DIABETES CARE INC (TNDM) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 17, 2026.

What is TNDM's SEC CIK number?

TANDEM DIABETES CARE INC (TNDM)'s SEC Central Index Key (CIK) is 1438133. EDGAR lists every TNDM filing under that number.

Ask anything about TNDM

The research agent reads TNDM's filings, financials, insider trades and 13F holders, then answers with sources.